ETR:AFX Carl Zeiss Meditec (AFX) Stock Price, News & Analysis €60.60 -5.10 (-7.76%) As of 03/31/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Carl Zeiss Meditec Stock (ETR:AFX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Carl Zeiss Meditec alerts:Sign Up Key Stats Today's Range€59.60▼€63.7550-Day Range€48.12▼€69.6052-Week Range€54.60▼€123.75Volume302,374 shsAverage Volume94,405 shsMarket Capitalization$5.65 billionP/E Ratio32.39Dividend Yield1.82%Price TargetN/AConsensus RatingN/A Company OverviewCarl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.Read More… Remove Ads Receive AFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carl Zeiss Meditec and its competitors with MarketBeat's FREE daily newsletter. Email Address AFX Stock News HeadlinesCarl Zeiss Meditec's (ETR:AFX) Dividend Will Be Reduced To €0.60March 22, 2025 | finance.yahoo.comJ.P. Morgan Sticks to Their Sell Rating for Carl Zeiss Meditec (0DHC)March 13, 2025 | markets.businessinsider.comElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.April 1, 2025 | Brownstone Research (Ad)EQS-News: ZEISS VISUMAX 800 with SMILE pro software receives approval in ChinaFebruary 27, 2025 | markets.businessinsider.comCarl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Smaller Dividend Than Last YearFebruary 16, 2025 | uk.finance.yahoo.comCarl Zeiss Meditec's Profit Falls; Warns of Challenging Macroeconomic EnvironmentFebruary 12, 2025 | marketwatch.comCarl Zeiss Meditec stock falls on Q1 resultsFebruary 12, 2025 | msn.comEQS-News: Carl Zeiss Meditec achieves slight revenue growth in first three months of 2024/25February 12, 2025 | markets.businessinsider.comSee More Headlines AFX Stock Analysis - Frequently Asked Questions How have AFX shares performed this year? Carl Zeiss Meditec's stock was trading at €45.52 at the beginning of 2025. Since then, AFX stock has increased by 33.1% and is now trading at €60.60. View the best growth stocks for 2025 here. What other stocks do shareholders of Carl Zeiss Meditec own? Based on aggregate information from My MarketBeat watchlists, some other companies that Carl Zeiss Meditec investors own include Intel (INTC), Meta Platforms (META), NVIDIA (NVDA), Volkswagen (VOW3), AbbVie (ABBV), Chevron (CVX) and Siemens Aktiengesellschaft (SIE). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolETR:AFX CIKN/A Webwww.zeiss.com Phone+49-3641-2200FaxN/AEmployees4,950Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)€1.87 Trailing P/E Ratio32.39 Forward P/E Ratio20.74 P/E Growth2.83Net Income$185.59 million Net Margins7.03% Pretax MarginN/A Return on Equity8.49% Return on Assets7.03% Debt Debt-to-Equity Ratio7.41 Current Ratio2.13 Quick Ratio2.47 Sales & Book Value Annual Sales$2.64 billion Price / Sales2.14 Cash Flow€0.04 per share Price / Cash Flow1,398.28 Book Value€22.92 per share Price / Book2.64Miscellaneous Outstanding Shares93,178,085Free FloatN/AMarket Cap$5.65 billion OptionableNot Optionable Beta0.98 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (ETR:AFX) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredNew Pick (93% history of rising by May 8)We just posted a new recommendation. Keep in mind: You could have boosted the Netflix trade we issued to the p...InvestorPlace | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carl Zeiss Meditec AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Carl Zeiss Meditec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.